Announcements Trials
Browse Landscape

Phase

Phase 1/2 4Phase 1 2Phase 2 1

Status

Recruiting 1Completed 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 2Other hematologic neoplasm 1Lymphoid 1Head & Neck 1Gynecologic 1Genitourinary 1

Conditions

Neuroendocrine Tumors 60Breast Neoplasms 22Thyroid Neoplasms 20Neoplasms 20Multiple Endocrine Neoplasia Type 1 20Carcinoma, Renal Cell 20Melanoma 19Carcinoma, Non-Small-Cell Lung 19Adrenocortical Carcinoma 19Small Cell Lung Carcinoma 17Thyroid Cancer, Papillary 16Colorectal Neoplasms 16Thyroid Carcinoma, Anaplastic 15Carcinoma, Neuroendocrine 15Carcinoma, Medullary 14Prostatic Neoplasms 13Pheochromocytoma 13Pancreatic Neoplasms 13Lung Neoplasms 13Carcinoma, Hepatocellular 13Carcinoid Tumor 13Insulinoma 12Uterine Cervical Neoplasms 11Squamous Cell Carcinoma of Head and Neck 11Neoplasm Metastasis 11Head and Neck Neoplasms 11Adenocarcinoma, Follicular 11Salivary Gland Neoplasms 10Pituitary Neoplasms 10Colonic Neoplasms 10

Interventions

relacorilant 1pembrolizumab 1fluorodopa F 18 16-fluorodopamine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Endocrine System Diseases × Endocrine × Clear all
NCT00004847 2026-05-07

Diagnosis of Pheochromocytoma

National Institutes of Health Clinical Center (CC)

Phase 1 Recruiting
3,000 enrolled
Endocrine

Endocrine System Diseases, Pheochromocytoma

NCT04373265 2024-02-23

Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol)

Corcept Therapeutics

Phase 1 Completed
15 enrolled
Endocrine

ACTH Syndrome, Ectopic, Adrenal Cortex Neoplasms, Adrenal Gland Diseases, Adrenocortical Hyperfunction, Cushing Syndrome, Diabetes Mellitus, Type 2, Endocrine System Diseases, Hyperglycemia, Hypertension, Pathologic Processes, Glucose Intolerance, Adrenocortical Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡